Scholar Rock Holding (SRRK) Interest Expenses (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Interest Expenses of $2.4 million for Q1 2026, up 15.46% year-over-year from $2.1 million in Q1 2025, and down 17.06% quarter-over-quarter from $2.9 million in Q4 2025.
Scholar Rock Holding (SRRK) Interest Expenses (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Interest Expenses history runs 10 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 15.46% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $8.9 million (up 20.24% YoY), while the FY2025 annual figure was $185.5 million, down 36.69% from the prior year.
- Interest Expenses for Q1 2026 stood at $2.4 million, down from $2.9 million in the prior quarter.
- The five-year high for Interest Expenses was $159.6 million in Q3 2025, with the low at $748000.0 in Q2 2022.
- The 5-year median for Interest Expenses is $2.4 million (2026), against an average of $20.6 million.
- The sharpest annual moves came in 2022 and 2025: Interest Expenses slumped 98.4% in 2022, then soared 5280.62% in 2025.
- Scholar Rock Holding's Interest Expenses stood at $1.7 million in 2022, then grew by 19.6% to $2.0 million in 2023, then slipped by 19.1% to $1.6 million in 2024, then soared by 76.89% to $2.9 million in 2025, then dropped by 17.06% to $2.4 million in 2026.
- Business Quant data shows SRRK's Interest Expenses at $2.4 million in Q1 2026, $2.9 million in Q4 2025, and $159.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | 206.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 206.53 Mn |
| Jun 30, 2026 | 206.53 Mn |
| Mar 31, 2026 | 2.37 Mn |
| Mar 31, 2026 | 2.37 Mn |
| Dec 31, 2025 | 2.86 Mn |
| Dec 31, 2025 | 2.86 Mn |
| Sep 30, 2025 | 159.64 Mn |
| Sep 30, 2025 | 159.64 Mn |
| Jun 30, 2025 | 155.14 Mn |
| Jun 30, 2025 | 155.14 Mn |
| Mar 31, 2025 | 2.05 Mn |
| Mar 31, 2025 | 2.05 Mn |
| Dec 31, 2024 | 1.61 Mn |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | 2.97 Mn |
| Sep 30, 2024 | 2.97 Mn |
| Jun 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | 3.53 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.73 Mn |